1. Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions
   Meining Wang et al, 2016, Journal of Medicinal Chemistry CrossRef
2. Proteins associated with EGFR-TKIs resistance in patients with non-small cell lung cancer revealed by mass spectrometry
   Shaoyu Yang et al, 2016, Molecular Medicine Reports CrossRef
3. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
   Ranjit K. Mehta et al, 2020, Clinical Cancer Research CrossRef
4. Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
   Jennifer Novak et al, 2022, Cancers CrossRef
5. E3 Ubiquitin Ligase CHIP Inhibits the Interaction between Hsp90β and MAST1 to Repress Radiation Resistance in Non-Small-Cell Lung Cancer Stem Cells
   Bo Tan et al, 2022, Stem Cells International CrossRef
6. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation
   Martin McLaughlin et al, 2017, BMC Cancer CrossRef
7. Preferential radiosensitization to glioblastoma cancer stem cell‑like cells by a Hsp90 inhibitor, N‑vinylpyrrolidone‑AUY922
   Toshiaki Tani et al, 2022, Oncology Letters CrossRef
8. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer
   Ganji Purnachandra Nagaraju et al, 2019, International Journal of Cancer CrossRef
9. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922
   Annett Kühnel et al, 2019, Cells CrossRef
10. Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review)
    Biaoxue Rong et al, 2017, International Journal of Oncology CrossRef
11. EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC
    Teppei Yamaguchi et al, 2024, Cancer Genetics CrossRef
12. Cancer Chemoprevention Effects of Geldanamycin and 17-AAG in Human Oral Squamous Cell Carcinoma
    Eun Ju Lee, 2018, The Korean Journal of Clinical Laboratory Science CrossRef
13. Progress of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
    德转 达, 2021, Advances in Clinical Medicine CrossRef
14. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators
    Şule Kale et al, 2020, Naunyn-Schmiedeberg's Archives of Pharmacology CrossRef
15. Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas
    Harvey Schwartz et al, 2015, Cell Stress and Chaperones CrossRef
16. Ubiquitin‐specific protease 8 is a novel prognostic marker in early‐stage lung adenocarcinoma
    Yunjung Kim et al, 2017, Pathology International CrossRef